BridgeBio Pharma (BBIO) presents a deeply negative liquidation posture as of March 31, 2026. Total assets of $1.37B are overwhelmed by total liabilities of $3.64B, producing a book stockholders' deficit of approximately $2.27B before applying liquidation haircuts. Under the liquidation lens, the deficit widens further. Applying standard recovery rates: cash and cash equivalents of $879.9M recover at 100% ($880M); available-for-sale securities of $60.3M recover near par ($60M); accounts receivable of $205.2M recover at 90-95% ($185-195M); inventory of $33.0M recovers at 60% ($20M); PP&E net of $4.9M recovers at 50-70% ($2-3M); operating lease ROU assets of $17.2M, intangible assets net of $27.4M, and equity method investments of $61.5M are assigned zero or negligible recovery in a liquidation scenario. Gross liquidated asset recovery totals approximately $1.15-1.20B. Against this, liabilities remain at face value: $2.65B in long-term debt (convertible notes plus deferred royalty obligations reported at carrying value net of $53.4M unamortized discount, with face principal of $2.505B in convertible notes plus $892.7M in deferred royalty obligations per the filing's narrative — total gross debt obligations exceed $3.3B); current liabilities of $816.4M including $135.5M in OtherLiabilitiesCurrent and $39.3M in employee-related liabilities; operating lease liabilities of $18.7M; deferred revenue of $17.9M ($6.1M current, $11.8M noncurrent). The asymmetry is structural and severe: liquidated assets of roughly $1.15-1.20B against liabilities of $3.64B produces an estimated liquidation deficit to common equity of approximately $2.4-2.5B, worse than book deficit due to haircuts on non-cash assets. The CLV/LLV/OLV metrics from MFFAIS ($49M, $255M, $287M respectively) confirm equity recovery is effectively nil under any reasonable liquidation scenario. The key change since the prior annual filing (FY2025 10-K, period end December 31, 2025) is the addition of $632.5M in 0.75% Convertible Senior Notes due 2033 (the 2033 Notes, issued January 2026), which added approximately $632M in face debt while approximately $82.5M of proceeds were used for a concurrent share repurchase (1,081,825 shares at $76.26). This incremental debt issuance materially increased the liability stack with no offsetting tangible asset addition of comparable magnitude. The deferred royalty obligation of $892.7M — representing the Funding Agreement (Attruby, 5-10% of global net sales, $950M cap) and the Royalty Purchase Agreement (Beyonttra EU royalties, $300M upfront, 145% hard cap at $435M) — is discussed extensively in MD&A but is not tagged as a separate XBRL line item; the filing does not separately disclose this component in XBRL tagging, embedding it within LongTermDebt. The accumulated deficit stands at $3.985B.
▼ Community Notes